Categories: Health

Transactions in connection with share buy-back program

Company announcement no. 10 – 26
14 April 2026

Transactions in connection with share buy-back program

On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 – 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules.

The purposes of the share buy-back programme are to meet obligations relating to acquisition of minority shareholders’ shares in NTG subsidiaries under the “Ring-the-Bell” concept, cover obligations arising under share-based incentive programmes, and potentially for other purposes such as payment in relation to potential M&A transactions.

During the period, NTG will purchase its own shares for an aggregate maximum amount of DKK 200,000,000, up to 1,250,000 shares (nominally DKK 25,000,000), corresponding to 5.52% of the current share capital of NTG.

The share buy-back programme will run from 5 March 2026 to 9 November 2026 at the latest, both days inclusive.

The following transactions have been made under the share buy-back program:

  Number of shares Average purchase price (DKK) Transaction value (DKK)
Accumulated, latest announcement 154,870   25,409,420
07 April 2026 12,503 171.7 2,146,933
08 April 2026 1,827 180.1 328,959
09 April 2026 1,128 179.5 202,481
10 April 2026 1,600 186.6 298,560
13 April 2026 2,452 184.2 451,768
Accumulated under the program 174,380   28,838,121

With the transactions stated above, NTG owns a total of 595,784 treasury shares, corresponding to 2.63% of the current share capital of NTG.

Details of each transaction are included as appendix.

Additional information

For additional information, please contact:

GlobeNews Wire

Recent Posts

Calidi Biotherapeutics Provides Required NYSE American Disclosure

May 22, 2026 18:00 ET  | Source: Calidi Biotherapeutics, Inc SAN DIEGO, May 22, 2026…

5 hours ago

GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse

Largo, FL, May 22, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by…

5 hours ago

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA,…

5 hours ago

AutoFlight V5000 Matrix Concludes ‘Heterogeneous Three-Aircraft Formation’ Flight, Officially Kicks Off Airworthiness Certification

KUNSHAN, China, May 24, 2026 /PRNewswire/ -- AutoFlight has successfully completed a demonstration flight of…

6 hours ago

C-Lingo: Transforming Chinese Language Learning in Vietnam with AI

HONG KONG, May 24, 2026 (GLOBE NEWSWIRE) -- As economic and cultural exchanges between Vietnam…

16 hours ago

Crypto News Today: AlphaPepe AI DEX Hits 5,000 Users While Bitcoin Price Prediction Eyes $180,000

MONACO, May 23, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

16 hours ago